Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis

Journal of Cataract and Refractive Surgery

Volumn 33, Issue 11, 2007, Pages 1978-1981

  Moshirfar, Majid ^a   Meyer, Jay J ^a   Espandar, Ladan ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOPENTOLATE; DOXYCYCLINE; ECONOPRED PLUS; GATIFLOXACIN; MOXIFLOXACIN; PREDNISOLONE ACETATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CASE REPORT; CLINICAL FEATURE; EYE EXAMINATION; FEMALE; HUMAN; INFECTION CONTROL; KERATITIS; KERATOMILEUSIS; MYCOBACTERIOSIS; MYCOBACTERIUM CHELONEI; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AMIKACIN; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLARITHROMYCIN; CORNEAL ULCER; DOXYCYCLINE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; KERATOMILEUSIS, LASER IN SITU; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM INFECTIONS, ATYPICAL; QUINOLINES;

EID: 35349006248     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2007.07.019     Document Type: Article

References (27)

1. Machat J.J. LASIK complications. In: Machat J.J., Slade S.G., and Probst L.E. (Eds). The Art of LASIK. 2nd ed. (1999), Slack, Thorofare, NJ 371-416
2. Lin R.T., and Maloney R.K. Flap complications associated with lamellar refractive surgery. Am J Ophthalmol 127 (1999) 129-136
3. Solomon R., Donnenfeld E.D., Azar D.T., et al. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey. J Cataract Refract Surg 29 (2003) 2001-2006
4. Dugel P.U., Holland G.N., Brown H.H., et al. Mycobacterium fortuitum keratitis. Am J Ophthalmol 105 (1988) 661-669
5. Scheld W.M. Maintaining fluoroquinolone class efficacy: review of influencing factors. [editorial]. Emerg Infect Dis 9 (2003) 1-9
6. Neu H.C. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol 112 suppl (1991) 15S-24S
7. Goldstein M.H., Kowalski R.P., and Gordon Y.J. Emerging fluoroquinolone resistance in bacterial keratitis; a 5-year review. Ophthalmology 106 (1999) 1313-1318
8. Alexandrakis G., Alfonso E.C., and Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 107 (2000) 1497-1502
9. Mather R., Karenchak L.M., Romanowski E.G., and Kowalski R.P. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol 133 (2002) 463-466
10. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136 (2003) 500-505
11. Abshire R., Cockrum P., Crider J., and Schlech B. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther 26 (2004) 191-196
12. Brown-Elliott B.A., Wallace Jr. R.J., Crist C.J., et al. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother 46 (2002) 3283-3285
13. Gillespie S.H., Morrissey I., and Everett D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 50 (2001) 565-570
14. Hyon J.-Y., Joo M.-J., Hose S., et al. Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. Arch Ophthalmol 122 (2004) 1166-1169
15. Ford J.G., Huang A.J.W., Pflugfelder S.C., et al. Nontuberculous mycobacterial keratitis in south Florida. Ophthalmology 105 (1998) 1652-1658
16. John T., and Velotta E. Nontuberculous (atypical) mycobacterial keratitis after LASIK: Current status and clinical implications. Cornea 24 (2005) 245-255
17. Hamam R.N., Noureddin B., Salti H.I., et al. Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone. Ophthalmology 113 (2006) 950-954
18. Biswell R. Cornea. In: Vaughan D., Asbury T., and Riordan-Eva P. (Eds). General Ophthalmology. 15th ed. (1999), Appleton & Lange, Stamford, CT 119-141
19. Eiferman R.A., and Stagner J.I. Intraocular penetration of amikacin; iris binding and bioavailability. Arch Ophthalmol 100 (1982) 1817-1819
20. Stroman D.W., Dajcs J.J., Cupp G.A., and Schlech B.A. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%; a new topical fluoroquinolone. Surv Ophthalmol 50 suppl 1 (2005) S16-S31
21. Hooper D.C. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 2 (1999) 38-55
22. Tanaka M., Wang T., Onodera Y., et al. Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother 6 (2000) 131-139
23. Höfling-Lima A.L., de Freitas D., Mello Sampaio J.L., et al. In vitro activity of fluoroquinolones against Mycobacterium abscessus and Mycobacterium chelonae causing infectious keratitis after LASIK in Brazil. Cornea 24 (2005) 730-734
24. de la Cruz J., Behlau I., and Pineda R. Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy. J Cataract Refract Surg 33 (2007) 1318-1321
25. Chandra N.S., Torres M.F., Winthrop K.L., et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am J Ophthalmol 132 (2001) 819-830
26. Gelender H., Carter H.L., Bowman B., et al. Mycobacterium keratitis after laser in situ keratomileusis. J Refract Surg 16 (2000) 191-195
27. Chung M.S., Goldstein M.H., Driebe Jr. W.T., and Schwartz B.H. Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. Am J Ophthalmol 129 (2000) 382-384